Dexcom's new CGM replacement policy puts profits over patients' lives. While 37.3 million Americans with diabetes rely on continuous glucose monitors to prevent life-threatening complications, Dexcom now limits replacements for failed sensors to just three per year. When their adhesive fails - during everyday activities like exercising or showering - patients must choose between paying $400 monthly for replacements or risking their health by going without this essential monitoring device. Despite their $4 billion annual revenue, Dexcom is forcing patients to bear the cost of their product failures, highlighting the urgent need for FDA intervention.